

Charity Registration No. 1134859/SC039721

Company Registration No. 07127101 (England and Wales)

**REPORT OF THE TRUSTEES AND
AUDITED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
FOR
NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees

Mr R Bains
Ms H Ball (Treasurer)
Ms R Campbell
Mr S Collins (Chair)
Mr R Flowerdew (Deputy Chair)
Professor P Taylor
Ms R Ulyett
Mrs A Woolf
Ms C Ward
Ms M Ward

CEO

Mr P Foxton

Charity number

1134859/ SC039721

Company number

07127101

Registered office

Suite 3, Beechwood
Grove Business Park
White Waltham
Maidenhead
Berks
SL6 3LW

Auditors

Moore Kingston Smith LLP
The Shipping Building
The Old Vinyl Factory
Blyth Road
Hayes
UB3 1HA

Bankers

HSBC
35 High Street
Maidenhead
SL6 1JQ

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
CONTENTS**

	Page
Trustees' report	1-12
Statement of Trustees' responsibilities	13
Statement as to disclosure to our auditors	14
Independent auditors' report	15-19
Consolidated Statement of financial activities	20
Company Statement of financial activities	21
Consolidated and Company Balance Sheets	22
Consolidated Statement of Cash Flows	23
Notes to the accounts	24-38

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

Trustee Report 2025

The Trustees present their report and audited consolidated accounts for the year ended 31 December 2025. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements of the Charity.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's governing document, the Charities Act 2011, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015 as updated in 2019).

Chair's Report

I am pleased to present the 2025 Annual Report, which reflects a further year of commitment, service and impact. NRAS exists to inform and support people living with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA), and throughout the year the organisation has continued to deliver this purpose through the professionalism, dedication and generosity of its staff and volunteers. Their work has ensured that beneficiaries accessing our services feel supported, valued and safe. On behalf of the Board of Trustees, I would like to thank all those who have contributed their time, skills and expertise during the year; their ongoing commitment remains central to the charity's ability to achieve its objectives and deliver public benefit.

Significantly, 2025 saw the launch of our new three-year strategy. This began life with a substantial program of stakeholder engagement in which we canvassed the views of staff, volunteers, healthcare professionals, commissioners and most importantly people living with RA and JIA. The resulting strategy has created clear organisational goals based around four key themes; informing and educating, supporting and empowering, campaigning and research, and funding and resilience. Through delivering it we aim to dramatically increase the number of people we reach both directly, through engagement with our services, or indirectly through our influencing work and as we provide an important patient voice in research. The new strategic goals are embedded in our future business plans and we are already taking steps to realise our ambitions by introducing a new healthcare engagement manager role and updating our young people and families strategy.

For people living with RA and JIA, and their loved ones, the healthcare environment remains challenging. Rheumatology departments are still wrestling with workforce shortages leading to services becoming increasingly stretched. For those awaiting diagnosis delays are still common and more needs to be done to raise awareness of symptoms both with the public and with primary care providers. Our survey of services in Wales, published in April 2025 highlighted some of these problems with over half of those recently diagnosed having to see a GP at least three times prior to diagnosis. The survey also highlighted the lack of signposting to services provided by patient organisations, like NRAS. With the NHS 10-year plan and its focus on prevention and community-based care it has never been more important that people have access to high quality evidence led support and education. NRAS, with its Helpline, Right Start programme and online educational tools is well placed to provide this.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

Financially this has been another positive year for the organisation. It's good to see that our focus and investment in fundraising have led to a significant increase in income over 2024, despite a fall in legacy receipts and money from pharmaceutical companies compared to the previous year. This has been driven by a significant increase in Trusts and Grants income, including the first year of the multi-year funding from the National Lottery Community Fund and significant contributions from Garfield Weston Foundation and The Clive Garner Memorial. Costs also increased, driven partially by the effects of increase in National Insurance contributions as well as other inflationary pressures. Consequently, the organisation closed the year with a modest net gain of £34.1k, which was an improvement on the level originally budgeted, leaving NRAS well placed to deliver its strategic objectives in the coming years.

Finally, I would like to thank two individuals who have recently stepped down from their roles and made significant contributions to NRAS. Helen Ball, Finance Director for seven years, strengthened our finance systems, governance and IT infrastructure, leaving NRAS in a strong financial position. I would also like to thank Professor Peter Taylor, who served voluntarily as Chief Medical Advisor for over ten years, and played a key role in campaigns that significantly improved outcomes for people living with these conditions.

A handwritten signature in black ink, appearing to read 'S. Collins', with a stylized, cursive script.

Simon Collins
Chair of Trustees

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

Our purpose and activities

Guidance from the Charity Commission has been used to review and develop NRAS's aims and objectives so that activities are clearly focused to derive good public benefit.

Objectives and activities

The objects of the Charity (the "Objects") are for the public benefit to promote the relief of people living with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA) by:

- Raising awareness and understanding of RA and JIA, including awareness of the severity of the diseases and their social and economic costs;
- Providing information on RA and JIA, including information on their treatments and drugs available;
- Advancing all aspects of the care and treatment of RA and JIA and the management of these diseases in their totality;
- Providing education on the diseases generally and to individuals and their families and carers in all aspects of RA and JIA, including their treatment and management, and providing information about available support;
- Supporting individuals across the UK in relation to RA and JIA and their families and carers, including putting people in touch with each other to encourage self-help and support where appropriate;
- Working alongside NHS rheumatology health professionals across the UK to provide the best care for patients as well as support the clinical staff in their roles.

Our vision and purpose

Our vision is a future where everyone with RA and JIA can thrive.

Our purpose is to inform and support people with RA and JIA and campaign for improvements to care and treatments.

We will achieve our vision by focusing on four main areas of work:

Informing and Educating: to greatly increase understanding of RA and JIA and the number of people accessing our services

Supporting and Empowering: to support more people to safely self-manage their health by improving the relevancy, accessibility, visibility and reach of our services

Campaigning and Research: to support research and campaign to improve access to high quality care and treatments

Raising funds and building a resilient organisation: to build a strong organisation that raises more money from diverse sources to meet the needs of patients

Our principal activities

We are committed to providing support, evidenced-based information, services, education, campaigning and patient advocacy of the highest quality to, and on behalf of all, those affected by RA and JIA across the UK as well as their families. We also support health professionals in the field of rheumatology and primary care through the provision of free Healthcare Professional membership of NRAS and access to a free patient referral programme and information so that we can help them to help their patients.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

Our front-line services include:

- A Helpline which operates 30 hours per week and is managed by a team of six colleagues;
- An online peer support community;
- Local and virtual groups;
- A peer-to-peer telephone support programme;
- A supported self-management modular e-learning programme;
- Information booklets;
- Websites packed with information and downloadable resources;
- Patient events (both in person and virtually)
- A membership scheme

Living with RA and JIA is not just about having physical and medical needs. These incurable diseases have a huge impact on emotional wellbeing and quality of life on both the individual and their family. We will continue to strive to help people by supporting **all** their needs in a holistic way whether physical, medical, emotional, mental, social, economic and/or employment related needs as well as those relating to access to benefits.

We are at the table at a national level whenever standards and guidelines, RA/JIA pathways and access to treatment are being discussed. We conduct our own social research and publish key reports on a topic of importance to people with RA/JIA periodically.

Translational scientific and medical research has revolutionised the field of auto-immune conditions such as RA and JIA in the last few decades and whilst we do not fund medical research ourselves, we do support a growing number of academic and clinical research studies throughout the UK on an ongoing basis. We also support recruitment to clinical studies and provide expert volunteers to advise on issues of Patient and Public Involvement.

In 2025, we started work on designing a range of short educational modules to complement our online educational programme, SMILE RA.. These videos aim to present the key highlights from each of our modules in an informative way and will be accessible on a variety of digital platforms. We also ran an awareness campaign to encourage more health professionals to utilise the SMILE modules for patient education by signposting people living with RA to register for the programme.

In addition, we undertook a change programme on our Right Start service which provides information and advice to those newly diagnosed through a one-to-one telephone consultation. This included improving the way people book an appointment, improving the call waiting facility and preparing to introduce full translation services in 2026. We launched two updated publications in 2025, 'Stress Matters' and 'Relationships Matters'. We also began work on a new publication on Menopause and RA including holding focus groups with patients and collaborating with other leading charities in the field. This publication was released in February 2026.

In April 2025 we published our report into Rheumatology services in Wales. This report highlighted concerns about the time to diagnosis for people living with RA, the lack of signposting to patient organisations for support with self-management and that people living with the condition believe that their disease is unstable and could be better controlled. We continue to use this report in advocating for improvements to services in Wales and have seen significant improvement in referral to our Right Start programme from Welsh rheumatology teams.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025

Achievements, performance and financial review

Total Income: £1.71m (2024: £1.54m)



Overall income was up by 11% on 2024. The year’s performance was again boosted by legacy bequests where reported income reached £739.9k, representing over 43% of the Charity’s total income. Whilst this reported legacy income was a drop of over 6% on prior year it was still our second-best legacy performance ever and reflects the trend we have seen in recent years for larger individual bequests. We remain immensely grateful to our very generous benefactors whose gifts enable us to continue to invest in our services and deliver new innovations which are so needed especially as we enter a health environment more focussed on delivering services digitally.

Income from donations and gifts was £489.72k, a welcome increase of 8% on 2024 that reflects work commenced in 2025 to reverse a trend of falling regular giving. These figures also include funds received from pharmaceutical companies who manufacture and market medicines for RA and/or JIA. This income amounted to £96.5k in 2025 (2024: £121.6k), equating to 5.6% of total income (down from 7.9% in 2024). We consider all donations and partnerships with pharmaceutical companies carefully and work within the accepted codes of practice set down by the Association of the British Pharmaceutical Industry (ABPI). As well as helping to fund the core services that we deliver to our beneficiaries, these relationships provide NRAS with access to important information about clinical trial data and help to inform and educate our team members on RA and JIA. As a key expert partner NRAS contributes to advisory boards and employee training, as well as providing support in the development of their own patient-facing support resources.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

The Charity also operates a membership scheme for those living with RA or JIA, their families and health care professionals which provides monthly newsletters, a bi-annual magazine full of interesting articles and information and two online meetings a year. Income from the membership scheme totalled £75.8k in 2025 (2024: £81.3k).

Support for NRAS was also received through grants from trusts and foundations and in 2025 this amounted to £299.4k (2024: £105.3k), representing a 184% increase. Of this, we gratefully received £134.7k from the National Lottery Community Fund which relates to the first year of a three-year grant totalling £404,692; £50k from Garfield Weston and £50k from Clive Garner Memorial Trust. We would also like to express particular thanks to the following organisations who all donated £2,000 or over: Joseph Strong Frazer Trust; Lady Hind; Parker Foundation; Hospital Saturday Fund; Ludlow Trust CM Lowe CT; Colefax Charitable Trust; Vandervell Foundation; Joan Ainslie Trust; Derek Draper Trust; Tula Trust; JW Patterson.


We continue to work with academic partners, pharmaceutical companies or other organisations in the field of social research to help develop and deliver new services to best meet the needs of all those we serve as well as campaign to effect change with government, the NHS and those who commission health and social care services. In 2025 income generated from research activities totalled £21.5k (2024: £16k).

All income received through fundraising in 2025 contributed to enabling the Charity to provide a full programme of resources, activities and support which benefits those living with RA and JIA in the UK, their families, schools and the healthcare professionals who care for them. NRAS would like to acknowledge and thank all the individuals, companies, trusts and foundations that have supported our work this year.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

Total expenditure £1.77m (2024: £1.57m)

Overall expenditure in the year increased by 12.3% to £1.77m. Of this total amount, £332.9k was spent on raising funds compared to £304.7k in 2024. A total of £1.44m (2024: £1.27m) was spent on our charitable activities delivering our full range of services.



Average full-time equivalent employee numbers totalled 29, an increase of 3.0 since 2024 with employment costs rising by 17.9% reflecting the creation of new posts, employer's National Insurance rises from April 2025 (from 13.8% to 15%) and the annual cost of living increases awarded to all staff.

The Charity reported a consolidated net surplus of £34.1k in 2025, up from £26k in 2024.

The Charity's wholly owned trading subsidiary, NRAS Community Services Limited, was largely dormant in 2025. The company reported a £1k net loss on its activities in 2025.

Balance sheet shows net assets of £2.08m

Net assets in the year increased by £34.1k reflecting:

- Gains on revaluation of investments of £88.8k, representing a 8.1% growth in the fund
- A decrease of £132k on cash at bank and short-term investments including £33.6k transfer to investments
- An increase of £77k on fixed assets and other current assets, primarily reflecting an increase in accrued legacy income.
- A £20k provision for building dilapidation costs

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES’ REPORT (INCLUDING DIRECTORS’ REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025

Reserves policy


Unrestricted, undesignated reserves totalled £1.1m at the end of the year

Unrestricted, undesignated reserves as at 31 December 2025 totalled £1,129k (2024: £1,099k) giving rise to an operating cost coverage of 7.66 months (2024: 8.37).

The Charity’s reserves policy requires that it holds a minimum of six months’ operating costs in reserves which at 31 December 2025 amounted to £883k (2024: £787k). This leaves free reserves as at 31 December 2025 of £245k (2024: £311.0k). Free reserves are defined as unrestricted funds which have not been earmarked and may be used generally to further the charity’s objectives.

As in previous years, the Charity continues to set aside designated reserves to support the continued delivery of its core services for the upcoming period and to cover potential investment losses. These designated funds in aggregate amounted to £415.6k as at 31 December 2025. The Board continues to set aside additional funds which are designated for service development (£236.8k), extensive awareness raising campaigns (£91.8k) and an estate development fund (£100k) bringing total designated funds to £844.2k (2024: £925.2k).

Restricted funds, relating to the National Lottery Community Fund grant and the Scottish Survey, increased from £20.1k as at 31 December 2024 to £104.5k as at the end of 2025.



We will work hard to ensure that our funds are used judiciously so that we return the biggest benefit to our beneficiaries for each pound invested. We will continue the expansion of our services to make them more inclusive, broaden our digital offerings as well invest in campaigns to raise awareness of RA and JIA.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

Going concern

The charity continues to prepare financial statements on the basis that it is a going concern.

Our healthy cash balance and investment portfolio means that we have sufficient liquidity to ensure that we can meet our future obligations as they become due for the foreseeable future.

Fundraising practices

The charity complies with the regulatory standards for fundraising. We are registered with the Fundraising Regulator and are committed to the Fundraising Promise and adherence to the Code of Fundraising Practice. This report covers the requirements charities must follow as set out in the Charities Act 2011 and the Charities Social and Protection Act 2016.

Our fundraising effort involves encouraging donations through a variety of events, applying for funds from grant-making bodies and operating a weekly lottery. Our fundraising team comprises paid employees only and we do not use the services of any professional fundraisers. All direct marketing is undertaken by the fundraising department to ensure that it is not unreasonably intrusive nor persistent. All marketing material contains clear instructions on how a person can be removed from mailing lists.

We operate our lottery compliantly under licence from our local authority and all administration is handled by a certified External Lottery Manager with the Gambling Commission.

Our website outlines our complaints policy for the public and clearly explains how an individual can complain. We received no complaints this year in relation to fundraising activities.

We have published our vulnerable persons policy on our website. In addition to our policy we have an agreed operating procedure to protect vulnerable people. Our fundraisers, who are all paid employees, are familiarised with the code of conduct to ensure that it is applied properly.

Investment Policy and Objectives

Longer-term assets are invested with the aim of at least maintaining the real value of capital (i.e. against inflation) within an appropriate risk profile. The Charity's investment objectives are to invest for the long-term (five years plus) in a diversified portfolio ensuring that there is sufficient liquidity available to fund any shortfalls or unfunded commitments.

Investments are managed by external professional fund managers as permitted by the relevant acts and the charity commission guidelines. The Charity aims to be a responsible investor and its professional fund managers are expected to take account of Environmental, Social and Governance (ESG) issues in their investment analysis and decision-making process and to engage with trustees when appropriate, including the provision of periodic reports covering ESG issues.

Investment performance reports are received quarterly from the fund managers and the Trustees review performance annually with the fund managers.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

Future plans

The Trustees approve and adopt strategic plans for the Charity every three years and detailed budgets are prepared annually to support these initiatives and demonstrate how the objectives will be delivered within the constraints of predicted funding available. The budget is reviewed on a quarterly basis and appropriate management decisions are taken in light of any material forecast variances.

The Charity published its 2025 – 2028 strategy during the year. It sets out how the Charity aims to increase its reach and be able to offer support and advice to more diverse communities. Work is already underway to extend and enhance our service provision and to improve awareness of RA and JIA in the wider community.

We expect to continue to work collaboratively to remove barriers to being able to access the right treatment, at the right time in the right place, provided by the right professional. We will continue to work to reduce discrimination within the workplace and the wider society towards people with inflammatory arthritis. We will also champion the best evidence-based healthcare provision no matter where in the UK someone lives and we will support all those who work within the health service to provide the best holistic care without being hampered by a system which prevents them from achieving this.

Structure, governance and management

Governing document

The Charity is controlled by its governing documents, the memorandum and articles, and constitutes a limited by guarantee company as defined by the Companies Act 2006.

The Charity is a company limited by guarantee and does not have any share capital.

None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute £1 each in the event of a winding up.

Trustees

The Trustees, who are also the directors for the purpose of company law, and who served during the year and to the date of approval of these accounts were:

Mr R Bains
Ms Helen Ball (Treasurer) (appointed 1 March 2026)
Mr RA Boucher (resigned 18 March 2025)
Ms R Campbell (appointed 20 January 2026)
Mr S Collins (Chair)
Mr R Flowerdew (Deputy Chair)
Mr J D Jordan (resigned 12 November 2025)
Professor P Taylor
Ms R Ulyett (appointed 25 November 2025)
Ms C Ward
Ms M Ward (appointed 3 October 2025)
Mrs A Woolf

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

As set out in the articles (as amended in June 2019), Trustees are required to retire after three years in office. A retiring trustee shall be eligible for re-election. Mr S Collins, Professor P Taylor and Mrs A Woolf therefore retired from office at the AGM on 17th June 2025 and sought re-election. Mr S Collins had served nine years at the time of his retirement this year but agreed to stand for re-appointment to ensure that there can be an effective handover to a new Chair in due course. All three trustees were duly re-elected, including Mr S Collins to continue as Chair.

Trustee induction and training

New Trustees are briefed on their legal obligations under Charity law, the content of the constitution and decision-making process, the business plan and recent financial performance of the Charity. As part of the process they meet key employees and other Trustees and may attend additional, relevant external training as required.

Organisation

The body of Trustees consists of not fewer than four and no more than twenty trustees and administers the Charity through the Senior Executives.

Related parties and co-operation with other organisations

None of our trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity with a supplier or other party with which the Charity transacts must be disclosed to the full board of trustees. In the current year no such related party transactions were reported.

Pay policy for senior staff

Remuneration for key management personnel is benchmarked against the voluntary sector and is set by the Trustees. The pay of senior staff is reviewed annually and normally increased in accordance with average earnings.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025

Risk management

The trustees have a risk management strategy including a formal risk evaluation which is carried out each year.

Risk Category	Mitigation and Actions
Financial performance and resilience Significant reduction in income streams and cashflow due to economic climate could affect the future viability of the Charity	- Fundraising strategy focusing on provision of regular, predictable, unrestricted income streams - Annual budget setting process and quarterly reviews with focus on cash flows and financing of operational plans - Monthly management accounts detailing key performance indicators and reserves coverage
Protecting the Charity's assets Market fluctuations caused by economic instability could negatively impact our investment portfolio and reduce the financial assets available to the Charity.	- Investment policy is set so as to maintain an appropriate and prudent risk strategy - Investments are managed by qualified external advisers
Maintaining a stable team Competitive recruitment markets resulting in high levels of vacancies could impact our ability to deliver our full range of core services and lead to over-reliance on key members of the team	- Regular benchmarking of remuneration packages to ensure competitive within the charity sector - Continue to prioritise staff wellbeing to maximise retention - Work continues on succession planning
IT Security Failure to ensure integrity and security of data could lead to data loss or theft, potentially resulting in fines, reputational damage and impact delivery of our core services	- Engagement of third party IT consultants to manage our IT systems and controls - Penetration testing conducted and training in place to alert staff to potential scams.
Data integrity and governance including GDPR Failure to meet our regulatory obligations could lead to fines, reputational damage and impact delivery of our core services	Appointment of third party data protection specialists to identify and monitor risks and ensure compliance with regulations
Attracting and retaining Trustees Failure to attract trustees with a range of skills could affect the future viability of the Charity	Continue to work with our network of partners and colleagues to identify suitable candidates

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

Auditors

Moore Kingston Smith acted as auditors to the charity for the year ended 31 December 2025. The trustees will consider the appointment of auditors for the forthcoming financial period.

Trustees' responsibilities in relation to the financial statements

The Trustees, who are also the directors of National Rheumatoid Arthritis Society for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that year.

In preparing these accounts the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP (FRS 102);
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- Prepare the accounts on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the accounts comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2025**

Statement as to disclosure to our auditors

In so far as the trustees are aware at the time of approving our Trustees' annual report:

- There is no relevant information, being information needed by the auditor in connection with preparing their report, of which the group's auditor is unaware, and
- The trustees, having made enquiries of fellow trustees and the group's auditor that they ought to have individually taken, have each taken all steps that he/ she is obliged to take as a trustee, in order to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.



S Collins
Chair of Trustees

16th June 2026



H Ball
Treasurer/ Trustee

16th June 2026

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES OF THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY

Opinion

We have audited the financial statements of National Rheumatoid Arthritis Society (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2025 which comprise the Consolidated Statement of Financial Activities, (including the Consolidated Summary Income and Expenditure Account), the Group and Parent Charitable Company Balance Sheets, the Consolidated Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2025 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES OF THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained in the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the trustees' annual report and from preparing a strategic report.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES OF THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 13, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES OF THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY

- Conclude on the appropriateness of the trustees' use of the going concern basis of **accounting** and, based on the audit evidence obtained, whether a material uncertainty exists related to **events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion.** Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES OF THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY

- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
- **We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.**
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.
- **Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.**

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Moore Kingston Smith LLP

Date: 16 June 2026

Danna Lukic (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

The Shipping Building
The Old Vinyl Factory
Blyth Road
Hayes, London
UB3 1HA

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)
FOR THE YEAR ENDED 31 DECEMBER 2025

		Unrestricted	Restricted	Total	Unrestricted	Restricted	Total
		funds	funds	funds	funds	funds	funds
		2025	2025	2025	2024	2024	2024
	Notes	£'000	£'000	£'000	£'000	£'000	£'000
<u>Income from:</u>							
Donations and legacies	3	1,219.6	10.0	1,229.6	1,241.7	0.4	1,242.1
Charitable activities	4	275.3	144.0	419.3	191.7	34.2	225.9
Other trading activities	5	8.1	0.0	8.1	14.5	0.0	14.5
Investment income	6	56.8	0.0	56.8	59.1	0.0	59.1
Total income		1,559.8	154.0	1,713.8	1,507.0	34.6	1,541.6
<u>Expenditure on:</u>							
Raising funds	7	332.9	0.0	332.9	304.7	0.0	304.7
Charitable activities	8	1,363.8	71.8	1,435.6	1,233.4	36.0	1,269.4
Total resources expended		1,696.7	71.8	1,768.5	1,538.1	36.0	1,574.1
Net income/(expenditure) before investments		(136.9)	82.2	(54.7)	(31.1)	(1.4)	(32.5)
Net gains/(losses) on investments	12	88.8	0.0	88.8	58.5	0.0	58.5
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
Net movement in funds		(48.1)	82.2	34.1	27.4	(1.4)	26.0
Fund balances at 1 January		2,023.3	20.1	2,043.4	1,997.4	20.0	2,017.4
Transfer between funds		(2.2)	2.2	0.0	(1.5)	1.5	0.0
Fund balances at 31 December		1,973.0	104.5	2,077.5	2,023.3	20.1	2,043.4

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 24 to 38 form part of these accounts.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
COMPANY STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)
FOR THE YEAR ENDED 31 DECEMBER 2025

		Unrestricted funds 2025	Restricted funds 2025	Total funds 2025	Unrestricted funds 2024	Restricted funds 2024	Total funds 2024
	Notes	£'000	£'000	£'000	£'000	£'000	£'000
Income from:							
Donations and legacies	3	1,219.6	10.0	1,229.6	1,241.7	0.4	1,242.1
Charitable activities	4	275.3	144.0	419.3	191.7	34.2	225.9
Other trading activities	5	8.1	0.0	8.1	14.5	0.0	14.5
Investment income	6	56.8	0.0	56.8	59.1	0.0	59.1
Total income		1,559.8	154.0	1,713.8	1,507.0	34.6	1,541.6
Expenditure on:							
Raising funds	7	332.9	0.0	332.9	304.7	0.0	304.7
Charitable activities	8	1,363.0	71.8	1,434.8	1,233.4	36.0	1,269.4
Total resources expended		1,695.9	71.8	1,767.7	1,538.1	36.0	1,574.1
Net income/(expenditure) before investments		(136.1)	82.2	(53.9)	(31.1)	(1.4)	(32.5)
Net gains/(losses) on investments	12	88.8	0.0	88.8	58.5	0.0	58.5
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
Net movement in funds		(47.3)	82.2	34.9	27.4	(1.4)	26.0
Fund balances at 1 January		2,026.0	20.1	2,046.1	2,000.1	20.0	2,020.1
Transfer between funds		(2.2)	2.2	0.0	(1.5)	1.5	0.0
Fund balances at 31 December		1,976.5	104.5	2,081.0	2,026.0	20.1	2,046.1

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 24 to 38 form part of these accounts.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
CONSOLIDATED AND CHARITY BALANCE SHEETS
FOR THE YEAR ENDED 31 DECEMBER 2025

	Notes	Group		Charity	
		2025 £'000	2024 £'000	2025 £'000	2024 £'000
Fixed assets					
Intangible assets	13	0.0	4.2	0.0	4.2
Tangible assets	13	27.5	28.8	27.5	28.8
Investments	14	1,221.7	1,099.3	1,221.7	1,099.3
		1,249.2	1,132.3	1,249.2	1,132.3
Current assets					
Debtors	15	241.0	129.0	241.0	132.1
Short term investments		201.8	261.5	201.8	261.5
Cash at bank and in hand		545.7	618.0	545.7	617.6
		988.5	1,008.5	988.5	1,011.2
Liabilities:					
Creditors: amounts falling due within one year	16	(140.2)	(97.4)	(136.7)	(97.4)
Net current assets		848.3	911.1	851.8	913.8
Total assets less current liabilities		2,097.5	2,043.4	2,101.0	2,046.1
Provisions		(20.0)	0.0	(20.0)	0.0
Total net assets		2,077.5	2,043.4	2,081.0	2,046.1
Income funds					
Unrestricted funds	18	1,973.0	2,023.3	1,976.5	2,026.0
Restricted funds	18	104.5	20.1	104.5	20.1
		2,077.5	2,043.4	2,081.0	2,046.1

The Trustees have prepared group accounts in accordance with section 398 of the Companies Act 2006 and section 138 of the Charities Act 2011 and constitute the annual accounts required by the Companies Act 2006 and are for circulation to trustees of the company.

These accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 and are for circulation to the members of the company.

The notes at pages 24 to 38 form part of these accounts.

The accounts were approved by the Board of Trustees on 16 June 2026



H Ball
Treasurer/Trustee

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025**

	Notes	Group		Charity	
		2025 £'000	2024 £'000	2025 £'000	2024 £'000
Cash flows from operating activities					
Cash used in operations	24	(141.8)	191.5	(141.4)	194.1
Investing activities					
Purchase of intangible fixed assets		0.0	0.0	0.0	0.0
Purchase of tangible fixed assets		(13.4)	(6.2)	(13.4)	(6.2)
Purchase of listed investments		(33.6)	(32.3)	(33.6)	(32.3)
Decrease/(Increase) in short term investments		59.7	(261.5)	59.7	(261.5)
Interest received		56.8	59.1	56.8	59.1
Net cash generated from/(used in) investing activities		<u>69.5</u>	<u>(240.9)</u>	<u>69.5</u>	<u>(240.9)</u>
Net decrease in cash and cash equivalents		<u>(72.3)</u>	<u>(49.4)</u>	<u>(71.9)</u>	<u>(46.8)</u>
Cash and cash equivalents at beginning of year		618.0	667.4	617.6	664.4
Cash and cash equivalents at end of year		<u>545.7</u>	<u>618.0</u>	<u>545.7</u>	<u>617.6</u>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

1 Accounting policies

Charity information

National Rheumatoid Arthritis Society is a private company limited by guarantee incorporated in England and Wales and Scotland. The registered office is Suite 3, Beechwood, Grove Business Park, White Waltham, Berkshire, SL6 3LW

1.1 Accounting convention

These accounts have been prepared in accordance with the charity's governing document, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £'000.

The accounts have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include listed investments and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Preparation of consolidated financial statements

These consolidated financial statements incorporate the financial statements of the Charity and its subsidiary undertaking, NRAS Community Services Limited, made up to 31 December 2025. Intercompany transactions, balances and unrealised gains on transactions between the Charity and its subsidiary are eliminated. Accounting policies of subsidiary undertakings have been changed where necessary to ensure consistency with the policies adopted by the Group. The income of the trading subsidiary is included in the Consolidated Statement of Financial Activities within other trading activities. Expenditure is included in support costs.

1.2 Going concern

At the time of approving the accounts, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future and at least for 12 months from approval of these accounts. This expectation is based on the strong investments and cash position, reflecting a significant amount of unrestricted funds and the financial performance of the Charity. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the accounts.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

1 Accounting policies

(Continued)

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is probable. If the amount is not known, the legacy is treated as a contingent asset.

The charity receives grants in respect of charitable activities run by the charity. Income from grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Subscription income is recognised on a rolling basis from the date of membership.

Income is measured at the fair value of the consideration received or receivable and represents amounts receivable for services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

1.5 Resources expended

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

Costs of raising funds includes costs related to fundraising events, merchandising and advertising;

Expenditure on charitable activities includes staff costs and support costs relating to different projects conducted during the year (see note 8).

Irrecoverable VAT is charged as an expense against the activity for which expenditure arose.

Support costs allocation

Support costs include both direct expenditure incurred on charitable activities and those costs which assist the work of the charity including office and administrative costs. They are all incurred directly in the furthering of the charity's aims and purposes. Distinction has been made for those costs relating to the raising of funds and to governance, these costs have been analysed separately.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities.

The bases on which support costs have been allocated are set out in Note 9.

Fundraising costs are specified in Note 7.

Governance costs are specified in Note 9.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to that category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

1 Accounting policies

(Continued)

1.6 Intangible and tangible fixed assets and depreciation

Intangible and tangible fixed assets costing over £500 are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Improvements to property	20% straight line or lease period if shorter
Website development	25% straight line
Fixtures, fittings & equipment	25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9 Short term investments

Short term investments include short term liquid investments with original maturities of more than three months but less than one year.

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

1.11 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.12 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employments of an employee or to provide termination benefits.

1.13 Leases

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

3 Donations and legacies

	Group and charity	
	2025	2024
	£'000	£'000
Donations and gifts	489.7	453.4
Legacies receivable	739.9	788.7
	<u>1,229.6</u>	<u>1,242.1</u>
<i>Analysis by fund</i>		
Restricted funds	10.0	0.4
Unrestricted funds	<u>1,219.6</u>	<u>1,241.7</u>
	<u>1,229.6</u>	<u>1,242.1</u>

4 Income from charitable activities

	Group and charity	
	2025	2024
	£'000	£'000
Subscriptions	75.8	81.3
Lottery income	22.6	23.3
Research studies	21.5	16.0
Grants	299.4	105.3
	<u>419.3</u>	<u>225.9</u>
<i>Analysis by fund</i>		
Restricted funds	144.0	34.2
Unrestricted funds	<u>275.3</u>	<u>191.7</u>
	<u>419.3</u>	<u>225.9</u>

5 Other trading activities

	Group and charity	
	2025	2024
	£'000	£'000
Merchandising and other trading income	<u>8.1</u>	<u>14.5</u>
	<u>8.1</u>	<u>14.5</u>

6 Investments

	Group and charity	
	2025	2024
	£'000	£'000
Income from listed investments	33.6	32.3
Interest income	<u>23.2</u>	<u>26.8</u>
	<u>56.8</u>	<u>59.1</u>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

7 Expenditure on raising funds

	Group and Charity	
	2025	2024
	£'000	£'000
Staging fundraising events	34.3	31.6
Staff costs	247.2	220.2
Support costs	40.8	40.6
Governance costs	10.6	12.3
Expenditure on raising funds	332.9	304.7
<i>Analysis by fund</i>		
Restricted funds	0.0	0.0
Unrestricted funds	332.9	304.7
	332.9	304.7

8 Expenditure on charitable activities

Group	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2025	2025	2025	2025	2025	2025
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	43.9	1.5	74.4	0.0	0.0	119.8
Staff costs	349.7	65.8	287.0	187.3	102.5	992.3
Share of support costs (see note 9)	81.6	0.0	122.4	40.8	40.8	285.6
Share of governance costs (see note 9)	10.6	0.0	10.6	10.6	6.1	37.9
	485.8	67.3	494.4	238.7	149.4	1,435.6
<i>Analysis by fund</i>						
Restricted funds	18.6	41.4	0.6	0.0	11.2	71.8
Unrestricted funds	467.2	25.9	493.8	238.7	138.2	1,363.8
	485.8	67.3	494.4	238.7	149.4	1,435.6

Group	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2024	2024	2024	2024	2024	2024
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	68.1	7.4	42.4	0.0	6.3	124.2
Staff costs	276.4	70.0	208.9	177.3	85.3	817.9
Share of support costs (see note 9)	81.2	0.0	121.8	40.6	40.6	284.2
Share of governance costs (see note 9)	12.3	0.0	12.3	12.3	6.2	43.1
	438.0	77.4	385.4	230.2	138.4	1,269.4
<i>Analysis by fund</i>						
Restricted funds	13.5	20.0	1.1	0.0	1.4	36.0
Unrestricted funds	424.5	57.4	384.3	230.2	137.0	1,233.4
	438.0	77.4	385.4	230.2	138.4	1,269.4

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

8 Expenditure on charitable activities

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2025 £'000	2025 £'000	2025 £'000	2025 £'000	2025 £'000	2025 £'000
Direct costs	43.9	1.5	74.4	0.0	0.0	119.8
Staff costs	349.7	65.8	287.0	187.3	102.5	992.3
Share of support costs (see note 9)	81.6	0.0	122.4	40.8	40.8	285.6
Share of governance costs (see note 9)	10.2	0.0	10.2	10.6	6.1	37.1
	485.4	67.3	494.0	238.7	149.4	1,434.8
Analysis by fund						
Restricted funds	18.6	41.4	0.6	0.0	11.2	71.8
Unrestricted funds	466.8	25.9	493.4	238.7	138.2	1,363.0
	485.4	67.3	494.0	238.7	149.4	1,434.8

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2024 £'000	2024 £'000	2024 £'000	2024 £'000	2024 £'000	2024 £'000
Direct costs	68.1	7.4	42.4	0.0	6.3	124.2
Staff costs	276.4	70.0	208.9	177.3	85.3	817.9
Share of support costs (see note 9)	81.2	0.0	121.8	40.6	40.6	284.2
Share of governance costs (see note 9)	12.3	0.0	12.3	12.3	6.2	43.1
	438.0	77.4	385.4	230.2	138.4	1,269.4
Analysis by fund						
Restricted funds	13.5	20.0	1.1	0.0	1.4	36.0
Unrestricted funds	424.5	57.4	384.3	230.2	137.0	1,233.4
	438.0	77.4	385.4	230.2	138.4	1,269.4

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

9 Support costs

Group	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2025	2025	2025	2024	2024	2024
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		20.3	20.3		30.5	30.5
IT	115.5		115.5	97.2		97.2
Office	61.1		61.1	80.0		80.0
Professional and consultancy fees	16.4		16.4	15.8	1.2	17.0
Irrecoverable VAT	32.9		32.9	24.1		24.1
Other overheads	61.6		61.6	71.6		71.6
Depreciation & dilapidations	38.9		38.9	36.1		36.1
Insurance		7.2	7.2		6.4	6.4
Auditors' remuneration:						
- Audit fees		21.0	21.0		17.3	17.3
- Other services		0.0	0.0		0.0	0.0
	326.4	48.5	374.9	324.8	55.4	380.2
Analysed between						
Fundraising (note 7)	40.8	10.6	51.4	40.6	12.3	52.9
Charitable activities (note 8)	285.6	37.9	323.5	284.2	43.1	327.3
	326.4	48.5	374.9	324.8	55.4	380.2

The above costs were allocated on a headcount basis.

Charity	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2025	2025	2025	2024	2024	2024
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		20.3	20.3		30.5	30.5
IT	115.5		115.5	97.2		97.2
Office	61.1		61.1	80.0		80.0
Professional and consultancy fees	16.4		16.4	15.8	1.2	17.0
Irrecoverable VAT	32.9		32.9	24.1		24.1
Other overheads	61.6		61.6	71.6		71.6
Depreciation & dilapidations	38.9		38.9	36.1		36.1
Insurance		7.2	7.2		6.4	6.4
Auditors' remuneration:						
- Audit fees		20.2	20.2		17.3	17.3
- Other services		0.0	0.0		0.0	0.0
Trustee expenses		0.0	0.0		0.0	0.0
	326.4	47.7	374.1	324.8	55.4	380.2
Analysed between						
Fundraising (note 7)	40.8	10.6	51.4	40.6	12.3	52.9
Charitable activities (note 8)	285.6	37.1	322.7	284.2	43.1	327.3
	326.4	47.7	374.1	324.8	55.4	380.2

The above costs were allocated on a headcount basis.

10 Trustees

None of the Trustees (nor any persons connected with them) received any remuneration during the year, and 2 trustees were reimbursed a total of £55 travelling and accommodation expenses (2024: £164 to one trustee).

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

11 Employees

Number of employees

Group & Charity	
2025	2024
Number	Number

The average monthly number of employees during the year was:

All employees - Group and Charity	34	30
-----------------------------------	----	----

The average monthly number of full-time equivalent employees during the year was:

All employees - Group and Charity	29	26
-----------------------------------	----	----

Employment costs

Group & Charity	
2025	2024
£'000	£'000

Wages and salaries	1,079.9	936.1
Pension costs	58.4	46.7
Social security	121.5	85.9
	<u>1,259.8</u>	<u>1,068.7</u>

The total amount of redundancy payments made by the Charity in the year was £nil (2024: £1,346).

The number of employees who received total employee benefits (excluding employer pension costs) of more than £60,000 is as follows:

	2025	2024
	Number	Number
£60,001 - £70,000	1	0
£80,001 - £90,000	1	0

Remuneration of key management personnel

The remuneration of key management personnel is as follows:

	2025	2024
	£'000	£'000
Aggregate Compensation	246.6	240.4

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

12 Net gains/(losses) on investments

	2025	2024
	£'000	£'000
Revaluation of investments	88.8	58.5

13 Tangible and intangible fixed assets - Group and Charity

	Intangible assets	Tangible assets		
	Website development	Improvements to property	Fixtures, fittings & equipment	Total tangible assets
	£'000	£'000	£'000	£'000
Cost				
At 31 December 2024	134.8	25.8	64.9	90.7
Additions	0.0	0.0	13.4	13.4
Disposals	0.0	0.0	0.0	0.0
At 31 December 2025	134.8	25.8	78.3	104.1
Depreciation				
At 31 December 2024	130.6	11.6	50.3	61.9
Charge for the year	4.2	5.2	9.5	14.7
Disposals	0.0	0.0	0.0	0.0
At 31 December 2025	134.8	16.8	59.8	76.6
Carrying amount				
At 31 December 2025	0.0	9.0	18.5	27.5
At 31 December 2024	4.2	14.2	14.6	28.8

14 Fixed asset investments - Group and Charity

	2025	2024
	£'000	£'000
Listed investments		
Market value at 1 January	1,099.3	1,008.5
Additions (including interest reinvested)	33.6	32.3
Revaluation	88.8	58.5
Market value at 31 December	1,221.7	1,099.3

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

15 Debtors

	Group		Charity	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Amounts falling due within one year:				
Trade debtors	13.6	7.0	13.6	7.0
Amounts owed by group undertakings	0	0.0	0	3.1
Prepayments and accrued income	227.4	122.0	227.4	122.0
	<u>241.0</u>	<u>129.0</u>	<u>241.0</u>	<u>132.1</u>

Other debtors include £25.3k relating to long term debtors receivable in greater than one year's time

16 Creditors: amounts falling due within one year

	Group		Charity	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Trade creditors	28.0	7.3	24.5	7.3
Other taxes and social security costs	40.7	12.8	40.7	12.8
Other creditors	27.8	44.2	27.8	44.2
Accruals and deferred income	43.7	33.1	43.7	33.1
	<u>140.2</u>	<u>97.4</u>	<u>136.7</u>	<u>97.4</u>

Deferred income included in the financial statements as follows:

	2025 £'000	2024 £'000
At 1 January	10.0	13.8
Movement during the year	<u>(1.6)</u>	<u>(3.8)</u>
At 31 December	8.4	10.0

17 Retirement benefit schemes

Defined contribution schemes

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £58.4k (2024: £46.7k).

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

18 Fund reconciliation

The income funds of the Charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

Unrestricted Funds

	Movement in funds				Balance at 31 December 2025 £'000
	Balance at 1 January 2025 £'000	Incoming resources 2025 £'000	Resources expended 2025 £'000	Transfer of funds 2025 £'000	
Unrestricted	1,098.1	1,559.8	(1,586.5)	57.4	1,128.8
Designated - to cover predicted operating losses in next year	375.2			(59.6)	315.6
Designated - to cover potential investment losses	100.0				100.0
Designated - service development fund	250.0		(13.2)		236.8
Designated - awareness raising fund	100.0		(8.2)		91.8
Designated - estate development fund	100.0				100.0
	2,023.3	1,559.8	(1,607.9)	(2.2)	1,973.0

	Movement in funds				Balance at 31 December 2024 £'000
	Balance at 1 January 2024 £'000	Incoming resources 2024 £'000	Resources expended 2024 £'000	Transfer of funds 2024 £'000	
Unrestricted	1,397.4	1,507.0	(1,479.6)	(326.7)	1,098.1
Designated - to cover predicted operating losses in next year	500.0			(124.8)	375.2
Designated - to cover potential investment losses	100.0	0.0		0.0	100.0
Designated - service development fund	0.0			250.0	250.0
Designated - awareness raising fund	0.0			100.0	100.0
Designated - estate development fund	0.0			100.0	100.0
	1,997.4	1,507.0	(1,479.6)	(1.5)	2,023.3

Restricted Funds

	Movement in funds				Balance at 31 December 2025 £'000
	Balance at 1 January 2025 £'000	Incoming resources 2025 £'000	Resources expended 2025 £'000	Transfer of funds 2025 £'000	
Information video in Hindi	0.4		(0.6)	0.2	0.0
Scottish Survey	0.0	10.0	(4.9)		5.1
Symptom checker	0.0	9.3	(11.2)	1.9	0.0
Welsh lottery funds	18.6		(18.6)		0.0
Translation of video resources into other languages	1.1		(1.2)	0.1	0.0
National Lottery Community Fund	0.0	134.7	(35.3)		99.4
	20.1	154.0	(71.8)	2.2	104.5

	Movement in funds				Balance at 31 December 2024 £'000
	Balance at 1 January 2024 £'000	Incoming resources 2024 £'000	Resources expended 2024 £'000	Transfer of funds 2024 £'000	
Information video in Hindi	1.1	0.4	(1.1)		0.4
JIA Right Start	1.1		(1.4)	0.3	0.0
Mission RA project	2.8	1.0	(4.9)	1.1	0.0
Q Lab project	15.0		(15.1)	0.1	(0.0)
Welsh lottery funds		20.0	(1.4)		18.6
Translation of video resources into other languages		9.9	(8.8)		1.1
Despatch of booklets to USA		3.3	(3.3)		0.0
	20.0	34.6	(36.0)	1.5	20.1

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

19 Analysis of net assets between funds - Group

	Restricted £'000	Unrestricted £'000	Total £'000
Fund balances at 31 December 2025 are represented by:			
Tangible fixed assets	0.0	27.5	27.5
Investments	0.0	1,221.7	1,221.7
Current assets/(liabilities)	104.5	723.8	828.3
	104.5	1,973.0	2,077.5

Fund balances at 31 December 2024 are represented by:

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	28.8	28.8
Investments	0.0	1,099.3	1,099.3
Current assets/(liabilities)	20.1	895.2	915.3
	20.1	2,023.3	2,043.4

Analysis of net assets between funds - Charity

	Restricted £'000	Unrestricted £'000	Total £'000
Fund balances at 31 December 2025 are represented by:			
Tangible fixed assets	0.0	27.5	27.5
Investments	0.0	1,221.7	1,221.7
Current assets/(liabilities)	104.5	727.3	831.8
	104.5	1,976.5	2,081.0

Fund balances at 31 December 2024 are represented by:

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	28.8	28.8
Investments	0.0	1,099.3	1,099.3
Current assets/(liabilities)	20.1	897.9	918.0
	20.1	2,026.0	2,046.1

20 Commitments under operating leases

At the reporting end date the group and charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2025 £'000	2024 £'000
Within one year	27.0	50.1
Between two and five years	0.0	27.0
	27.0	77.1

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

21 Subsidiary company

The charity owns the whole of the issued ordinary share capital of NRAS Community Services Ltd (company number: 8953247), a company registered in England.

The subsidiary is used for non-primary purpose trading activities.

All activities have been consolidated on a line by line basis in the Statement of financial activities.

The total net profit is gifted to the charity.

A summary of the results of the subsidiary is shown below:

	2025 £'000	2024 £'000
Turnover	0.0	0.0
Cost of sales	(0.8)	0.0
Gross profit	(0.8)	0.0
Administrative expenses	0.0	0.0
Net loss	(0.8)	0.0
Retained earnings brought forward in subsidiary	(2.7)	(2.7)
Gift aid to National Rheumatoid Arthritis Society	0.0	0.0
Retained earnings carried forward in subsidiary	(3.5)	(2.7)
The assets and liabilities were:		
The aggregate of the assets, liabilities and funds was:		
Assets	0.0	0.4
Liabilities	(3.5)	(3.1)
Total net assets	(3.5)	(2.7)
Called up share capital	0.0	0.0
Profit and loss reserve	(3.5)	(2.7)
	(3.5)	(2.7)

22 Related party transactions

There were no related party transactions in the year (2024: nil) requiring disclosure.

23 Capital Commitments

As at 31 December 2025 the Charity had capital commitments of £nil (2024: £nil).

NATIONAL RHEUMATOID ARTHRITIS SOCIETY
NOTES TO THE ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2025

24 Cash generated from/ (used in) operations	Group		Charity	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Surplus/ (loss) for the year	34.1	26.0	34.9	26.0
Adjustments for:				
Investment income recognised in profit or loss	(56.8)	(59.1)	(56.8)	(59.1)
Fair value gains and losses on investments	(88.8)	(58.5)	(88.8)	(58.5)
Gift aid donation from subsidiary	0.0	0.0	0.0	0.0
Depreciation and impairment of intangible fixed assets	4.2	21.8	4.2	21.8
Depreciation and impairment of tangible fixed assets	14.7	14.3	14.7	14.3
Movements in working capital:				
(Increase)/ decrease in debtors	(112.0)	274.8	(108.9)	276.9
Increase/ (decrease) in creditors	42.8	(27.8)	39.3	(27.3)
Increase / (decrease) in provisions	20.0	0.0	20.0	0.0
Cash generated from/(used in) operations	(141.8)	191.5	(141.4)	194.1

25 Analysis of changes in net funds

	At start of year £'000	Cash flows £'000	At end of year £'000
Cash and cash equivalents	618.0	(72.3)	545.7
Total	618.0	(72.3)	545.7